Product Description

Anti-Human FGFR2 Reference Antibody (Bemarituzumab, RUO)

Sizes: 100ug, 1mg

Catalogue Numbers: HB863016-100, HB863016-1000

Lead times: 1-2 weeks, if manufacturer has product in stock

Manufacturer/Ship Location: China

Description: Bemarituzumab (bema), a first-in-class humanized IgG1 monoclonal antibody, selectively binds to the 2b isoform of the fibroblast growth factor receptor (FGFR2b). Bemarituzumab (FPA144) is a first-in-class humanized immunoglobulin G1 monoclonal antibody specific to the splice-variant FGFR2b that inhibits binding of the ligands FGF7, FGF10, and FGF22. Specifically, bemarituzumab does not inhibit binding of FGF23, the ligand responsible for phosphate and vitamin D metabolism, thereby potentially avoiding the risk of hyperphosphatemia associated with pan-FGFR tyrosine kinase inhibitors. Bemarituzumab is also glycoengineered for increased affinity for the human Fc gamma RIII receptor expressed on natural killer cells, enabling enhanced antibody-dependent cell-mediated cytotoxicity.

Reactivity: Human

Host: Humanized

Applications: ELISA, Bioactivity: FACS, Functional assay

Alternate Names: FPA144, FPA-144, FPA114-A, 1952272-74-0

Clonality: Monoclonal

Isotype: IgG1-kappa

Target: K-sam, KSAM, CD332, Keratinocyte growth factor receptor, Fibroblast growth factor receptor 2, FGFR-2, FGFR2, KGFR, BEK

Purification: Protein A/G purified from cell culture supernatant.

Purity: >95% purity as determined by SDS-PAGE.

Expression System: Mammalian Cells

Storage and Stability: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.

Storage Buffer: 0.01M PBS, pH 7.4.

Form: Liquid

Accession: P21802

Endotoxin Level: Please contact the lab for this information.

Research Use Only